AU2020228514A1 — Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor

USPTO Abstract

The present disclosure addresses the problem of providing a new combination therapy that exhibits a superior anti-tumor effect in cancer patients who have a resistance to immune checkpoint inhibitors, said combination therapy involving (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidine-1-yl(pyrrolidine-1-yl)prop-2-en-1-one or a salt thereof. The present disclosure provides an anti-tumor agent for concomitant administration with an immune checkpoint inhibitor (excluding pembrolizumab) to cancer patients who have a resistance to immune checkpoint inhibitors, said anti-tumor agent including a (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidine-1-yl(pyrrolidine-1-yl)prop-2-en-1-one or a salt thereof as an active component.